Shares of Airsculpt Technologies climbed 7.3% to $5.12 on August 8 as traders placed bets ahead of the cosmetic-surgery company's second-quarter 2026 earnings report, due before the opening bell on Monday, August 10. The move breaks a week of choppy trading — the stock drifted from $4.81 to $4.96 before slipping to $4.77 — and raises the question of whether the results can sustain a rally for a name that remains deeply discounted to Wall Street's $6.25 average price target. Airsculpt Technologies Pops 7% Into Monday's Earnings — But Can a Body-Contouring Turnaround Story Outrun Its Balance Sheet?
Shares of Airsculpt Technologies jumped 7.3% to $5.12 on Friday as investors wagered the cosmetic body-contouring chain will show continued improvement when it reports second-quarter results before Monday's opening bell. The stock has seesawed between $4.77 and $4.96 all week, and no fresh analyst note or separate news event explains the pop — this is pure earnings anticipation in a thinly traded name.
• A Turnaround Quarter Needs to Prove the Spring Wasn't a Fluke
Management called Q1 a "key turning point," citing flat year-over-year revenue and the first positive same-center sales in over two years.
Revenue was $39.4 million with gross margins expanding to roughly 60% and adjusted EBITDA of $3.3 million. Consensus for Q2 is roughly $44.14 million in revenue and just $0.015 EPS — a seasonal step up. Management itself guided for "sequential improvement in both revenue and EBITDA in absolute dollars versus Q1." Missing that bar would undercut the entire recovery narrative.
• A Debt Refinancing Update Could Move the Stock More Than the Top Line
The CEO said the company is "in process to refinance our term loan" and promised details alongside Q2 results.
The existing debt carries an 8.42% interest rate , and after paying down $11 million in Q1, gross debt sits around $46 million with leverage below 2.5 times. A cheaper rate would directly improve cash flow for a company that posted a $2.4 million net loss last quarter.
• The Stock Is Still Cheap — or Fairly Priced, Depending on Who You Ask At $5.12, AIRS trades roughly 18% below the $6.25 average analyst target referenced in company materials, but two analysts tracked by StockAnalysis carry an average 12-month target of just $4.50 with a "Hold" consensus.
Full-year 2026 guidance calls for $151–$157 million in revenue and $15–$17 million in adjusted EBITDA , implying the stock trades at roughly two times sales — reasonable only if growth reaccelerates.
• New Procedures Are Promising but Unproven
Skin-excision procedures completed over 150 cases in Q1 but "have not yet been significant incremental revenue contributors."
Management claims these services could "unlock more than $100 million in long-term revenue across existing centers" — a bold figure for a company guiding to barely $154 million this year. Monday's call will show whether pilot volumes are scaling or stalling.